
Journal of Medicinal Chemistry p. 625 - 629 (1994)
Update date:2022-07-29
Topics:
Thurieau, Christophe
Simonet, Serge
Paladino, Joseph
Prost, Jean-Francois
Verbeuren, Tony
Fauchere, Jean-Luc
We report on the synthesis and pharmacological properties of a new series of thrombin inhibitors derived from hirudin carboxyl-terminal fragments.Two (arylphosphono)phenylalanines, p-PO3H2-L-Phe1 and m-PO3H2-L-Tyr, and one (carboxymethyl)phenylalanine, p-CH2COOH-L-Phe, were prepared and incorporated into position 63 of the modified hirudin's C-terminal dodecapeptide using the Fmoc solid-phase synthesis strategy.Substitution by any one of the residues led to very active analogs which doubled the thrombin time at low micromolar concentration (Ctt2) in vitro (1 μM < Ctt2 < 3 μM) and potently increased the activated partial thromboplastin time (APTT) ex vivo.These compounds displayed a higher potency in vitro and a longer duration of action in vivo than both the corresponding sulfated or phosphorylated tyrosine counterparts.
View MoreContact:+86-531-58668191 58668193 58668196 58661173
Address:No 55,Beixiaoxinzhuang West Street,Jinan City, Shandong Province
Contact:86-607-68073220
Address:1 ave na road jiahua st
Tianjin Tensing Fine Chemical Research Develop Centre
Contact:86-022-23718576,13032267585
Address:2-2-201,13 Guiyuan road,Huayuan Industry district,Tianjin,china
Melone Pharmaceutical Co., ltd
Contact:+86-411 82593920, 82593631
Address:No 232, JInma Roda, Development Zone, Dalian, China
NingBO Hong Xiang Biochem.Co.Ltd
website:http://www.hxbiochem.com
Contact:0574-66003444
Address:Ning Bo Bei Lun
Doi:10.1016/S0040-4039(00)61619-2
(1993)Doi:10.1002/ejoc.201900450
(2019)Doi:10.1039/C6CC09323J
(2017)Doi:10.1002/hlca.19940770213
(1994)Doi:10.1080/15257779508012405
(1995)Doi:10.1016/0045-6535(94)90008-6
(1994)